详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Oxaliplatin-induced hepatic sinusoidal obstruction syndrome

74| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

单位： [1]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Peoples R China

出处：

DOI：

ISSN：

关键词： Oxaliplatin hepatic sinusoidal obstruction syndrome clinical and pathological features

摘要：

Oxaliplatin (OXA) is a third-generation platinum anticancer drug that is mainly used for the treatment of metastatic colorectal cancer (CRC). Of note, hepatic sinusoidal obstruction syndrome (HSOS) induced by OXA has become a key concern for patients with CRC receiving chemotherapy with OXA in recent years. Splenomegaly, thrombocytopenia, abnormal liver function, and portal hypertension are some of the main clinical characteristics seen in patients with OXA-induced HSOS. Previous studies have suggested that oxidative stress, inflammatory damage, liver fibrosis, and platelet aggregation and adhesion may be involved in the pathogenesis of OXAinduced HSOS. Currently, there are no specific drugs for prevention and treatment of OXA-induced HSOS. In this review, we summarized the epidemiology, pathological characteristics, clinical predictive indicators, related mechanisms, possible prevention and treatment of OXA-related HSOS.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2020]版：

大类 | 2 区医学

小类 | 2 区药学 2 区毒理学

最新[2025]版：

大类 | 3 区医学

小类 | 2 区药学 2 区毒理学

JCR分区：

出版当年[2019]版：

Q1 TOXICOLOGY Q1 PHARMACOLOGY & PHARMACY

最新[2023]版：

Q1 PHARMACOLOGY & PHARMACY Q1 TOXICOLOGY

影响因子： 4.8 最新[2023版] 4.4 最新五年平均 4.099 出版当年[2019版] 3.908 出版当年五年平均 3.547 出版前一年[2018版] 4.221 出版后一年[2020版]

第一作者：

第一作者单位： [1]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Peoples R China

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Model establishment and microarray analysis of mice with oxaliplatin-induced hepatic sinusoidal obstruction syndrome [2]Magnetic Resonance Imaging Findings in Patients With Pyrrolizidine Alkaloid-Induced Hepatic Sinusoidal Obstruction Syndrome [3]Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome [4]Prognostic factors for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome: a multicenter study in China [5]Liver transplantation following late-onset hepatic sinusoidal obstruction syndrome occurred beyond 1-year postallogeneic hematopoietic stem cell transplantation [6]Timing and efficacy of transjugular intrahepatic portosystemic shunt in patients with pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome [7]X-linked Alport Syndrome in Children: Clinical and Pathological Features [8]Clinical characteristics, CT signs, and pathological findings of Pyrrolizidine alkaloids-induced sinusoidal obstructive syndrome: a retrospective study [9]Clinical and pathological features analysis of invasive breast cancer with microcalcification [10][The relative analysis of clinical endocrine features and pathological types of pituitary microadenomas].